On Thursday, Shares of Rite Aid Corporation (NYSE:RAD), subtract -2.69% and shut at $7.61 inside the end purchasing and offering session. The last exchanging scope of the stock ranges amongst $7.58 and $7.87. The business’ commercial center capitalization is $8.25 Billion with the aggregate fabulous loads of 1.05 billion. Rite Aid stores nationwide are now able to offer American Express Card Members participating in the Membership Rewards® program the opportunity to use Membership Rewards® points for eligible purchases. Eligible American Express Card Members, who have accumulated enough Membership Rewards® points to pay for their purchase, will be prompted to use points for their purchases after they swipe, tap or insert a Membership Rewards-enrolled American Express Card in-store. Rite Aid is the first pharmacy chain to offer Card Members the opportunity to use Membership Rewards® points for their purchases.
“At Rite Aid, we know how much our customers value choice and convenience, which is why we are excited to be the first pharmacy chain to offer American Express Card Members the opportunity to use Membership Rewards® points for their purchases,” said Ken Martindale, CEO of Rite Aid stores and president of Rite Aid Corporation. “Thanks to our partnership with American Express, in one quick and easy motion, our customers can use the points they’ve accrued through the Membership Rewards® program for their purchases, saving them both money and time.”
Specialized assessment: During the fifty two-week exchanging session the negligible rate at which extent cost exchanged, enrolled at $6.33 and came to max level of $8.30. The EPS of organization is walking around 0.13.
Shares of Palatin Technologies, Inc. (NYSEMKT:PTN), added 0.00% and shut at $0.520 inside the last exchanging session. The rest of the purchasing and offering scope of the stock levels among $0.49 and $0.55. The association’s commercial center capitalization is $42.25 million with the general uncommon loads of 108.04 million. Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with noteworthyunmet medical need and commercial potential, recently declared results for its first quarter ended September 30, 2016.
Bremelanotide – Under development for Hypoactive Sexual Desire Disorder (HSDD):
November 2016 stated positive Phase 3 clinical results – both pivotal trials met the pre-specified co-primary efficacy endpoints of improvement in desire and decrease in distress associated with low sexual desire, reflecting clinical meaningfulness and statistical significance.
Last patient visits for the efficacy portion of the trials were accomplished in the third quarter of calendar year 2016.
New Drug Application (NDA) submission to the FDA targeted for the second half of 2017.
Specialized examination: All through the fifty two-week exchanging session the negligible expense at which extent cost exchanged, enlisted at $0.36 and came to max level of $0.86. The EPS of association is by walking at -0.33.